Roper Technologies — Oct 23, 2025 release

We also acquired Orchard Software, which is being integrated into our Clinisys laboratory software business." "We are adjusting our full year 2025 DEPS guidance range to $19.90 - $19.95 compared to our previous guidance of $19.90 - $20.05 to reflect both our underlying trends and $0.10 of incremental DEPS dilution related to our third quarter acquisitions that were not reflected in our previous guidance. We continue to expect total revenue growth of approximately 13% and now expect organic revenue growth of approximately 6%," concluded Mr. Hunn. 1 For the fourth quarter of 2025, the Company expects adjusted DEPS of $5.11 - $5.16 including a $(0.05) impact from third quarter bolt-on acquisitions not reflected in previous guidance. The Company’s guidance excludes the impact of unannounced future acquisitions or divestitures, as well as potential share repurchases. New share repurchase program Roper's Board of Directors has authorized the repurchase of up to $3 billion of the Company's common stock. Repurchases may be made from time to time through open-market purchases or through privately negotiated transactions subject to market conditions, applicable legal requirements, and other relevant factors. The repurchase program does not obligate the Company to acquire any particular amount of its common stock and may be suspended at any time at the Company's discretion. The timing and number of shares repurchased will depend on a variety of factors, including the stock price, business and market conditions, corporate and regulatory requirements, alternative investment opportunities, acquisition opportunities, and other factors. Conference call to be held at 8:00 AM (ET) today A conference call to discuss th